Amy Dyken, controller at Fitzgerald Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Fitzgeralds financial statements. Below is selected financial information for the fiscal year ended June 30, 2014.

FITZGERALD PHARMACEUTICAL INDUSTRIES SELECTED BALANCE SHEET INFORMATION JUNE 30, 2014
Long-term debt
Notes payable, 9%		$1,018,000
7% convertible bonds payable		5,048,000
9% bonds payable		6,026,000
Total long-term debt		$12,092,000
Shareholders equity
Preferred stock, 6% cumulative, $57 par value, 106,300 shares authorized, 26,575 shares issued and outstanding		$1,514,775
Common stock, $1 par, 10,075,000 shares authorized, 1,007,500 shares issued and outstanding		1,007,500
Additional paid-in capital		4,001,800
Retained earnings		6,018,900
Total shareholders equity		$12,542,975

The following transactions have also occurred at Fitzgerald.

1.		Options were granted on July 1, 2013, to purchase 203,700 shares at $18 per share. Although no options were exercised during fiscal year 2014, the average price per common share during fiscal year 2014 was $20 per share.
2.		Each bond was issued at face value. The 7% convertible bonds will convert into common stock at 57 shares per $1,000 bond. The bonds are exercisable after 5 years and were issued in fiscal year 2013.
3.		The preferred stock was issued in 2013.
4.		There are no preferred dividends in arrears; however, preferred dividends were not declared in fiscal year 2014.
5.		The 1,007,500 shares of common stock were outstanding for the entire 2014 fiscal year.
6.		Net income for fiscal year 2014 was $1,547,000, and the average income tax rate is 45%.

For the fiscal year ended June 30, 2014, calculate the following for Fitzgerald Pharmaceutical Industries. (Round answers to 2 decimal places, e.g. $2.45.)

Diluted earnings per share